Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.00p -1.90% 51.50p 50.00p 53.00p 52.50p 51.50p 52.50p 23,055 11:18:18
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 0.4 -5.4 -8.6 - 38.53

Angle (AGL) Latest News

More Angle News
Angle Takeover Rumours

Angle (AGL) Share Charts

1 Year Angle Chart

1 Year Angle Chart

1 Month Angle Chart

1 Month Angle Chart

Intraday Angle Chart

Intraday Angle Chart

Angle (AGL) Discussions and Chat

Angle Forums and Chat

Date Time Title Posts
28/4/201714:20ANGLE 2016 – LIQUID BIOPSY TAKEOVER TARGET5,798.00
16/3/201720:00ANGLE [12.75p] TARA*S SHARE OF THE DECADE "TARGET PRICE Ј100.00 PER SHARE."3,646.00
08/10/201612:43Angle PLC 201130,115.00
02/12/201513:04Angle 2016 – Liquid Biopsy Takeover Target-
11/6/201508:16MrKeysersoze39.00

Add a New Thread

Angle (AGL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2017-04-28 14:56:5751.95962499.76O
2017-04-28 12:42:3450.365,0002,518.00O
2017-04-28 11:09:2152.007,0933,688.36O
2017-04-28 09:49:3851.108,0004,088.00O
2017-04-28 07:56:4051.252,0001,025.00O
View all Angle trades in real-time

Angle (AGL) Top Chat Posts

DateSubject
28/4/2017
09:20
Angle Daily Update: Angle Plc is listed in the Support Services sector of the London Stock Exchange with ticker AGL. The last closing price for Angle was 52.50p.
Angle Plc has a 4 week average price of 44.13p and a 12 week average price of 44.13p.
The 1 year high share price is 75.50p while the 1 year low share price is currently 44.13p.
There are currently 74,815,774 shares in issue and the average daily traded volume is 52,190 shares. The market capitalisation of Angle Plc is £38,530,123.61.
30/3/2017
09:20
alloa2003: Personally I think we will get there in the end but I have to laugh when people ignore what the market is telling us with the share price. If the shares were £1.20 everyone would be saying the price reflects the potential but some how when the shares are 44p the market has got it all wrong. Short term weakness in the share price should spur the management to getting more focused. This is not just any old product this is a life saver if we put aside the potential for the share price for one moment, this can save lives.
29/3/2017
17:32
4legs: To help making a decision whether to fully or partially sell out of Angle, I would be interested and appreciate any other poster's view as to whether the share price has for some time been manipulated for the benefit of a buyer(s) as it seems time and time again the price drops a penny on a relatively small greater amount of shares sold compared to those bought, in terms of quantity and value. Needless to say I am aware my selling off of shares is likely to have downward pressure on the share price for some time.
22/1/2017
21:05
fraybentos2: what is fair value for agl tiny revenues many competitors board of directors underperforming ctcs will not in the long term be used for cancer detection there is no proof of the value of ctcs for any other purpose no fda approval this year machine not fully automated delays in trials starting further dilution required absent deal lack of market confidence given revenues slow prospects and the above difficulties £10m perhaps on a good day so without a deal or pumped share price agl is worthless dilution required will be too high to make investable good news for mug punters the share price is higher than it should be bad news for mug punters the share price is falling
20/12/2016
18:51
adorling: At least those greedy Directors will need to get the share price to 129p before they can exercise those options granted in November! "The exercise price for the new share options is 64.50 pence per share, representing the Company's closing mid-market share price on 25 November 2016, being the latest practicable date prior to this announcement. The options are subject to service and/or performance conditions. The new share options granted to the executive directors have a term of ten years and are subject to the performance condition that the share price has risen by at least 100% from the share price when the option is issued."
12/12/2016
17:43
gary38: Willfy and Steve.I am here to get the best return for my investment and yes l thought that the share price would reach my target price but it fell back because of AN dealings with EFH which now coupled with the bonuses the share price struggling to stay up.And yes l did not get out for the reasons l mentioned above but a lot did and the result is where the share price is now.Great product but poor Management = poor value.
10/12/2016
18:23
m5: Elbillo8 Dec '16 - 20:33 - 4518 of 4553 No disrespect, ignoring a share price because you have faith in the Company can be a dangerous game IMHO. Are you saying that if the share price dropped to 30p you would be still comfortable? It is rare that the market gets it consistently wrong. At the end of the day the only thing that does matter is the share price I do not see anything with the share price at the moment that causes concern as the share price is trading within its range, however should it move outside of that range I would be paying attention, that applies to both the upper and lower levels. I would say flexibility in any share is the key, if you sell you can always buy back. I wish all holders the best of luck.
08/12/2016
18:09
banshee: From a liquid biopsy article about 12 months ago "Vermillion (NASDAQ:VRML) Founded in 1993, Austin based Vermillion has lost -78% of their share price value in the past 5 years giving the Company a market cap of just $86 million. Vermillion has developed the first FDA-cleared, multi-biomarker blood test that helps assess the risk of ovarian cancer prior to surgery. The Company brought in minuscule revenues in Q3 2015 making investors wonder just when this product offering will take off." Vermillion are the makers of the $600 OVA1 (now in v2 OVERA form ) test that has been mentioned a few times, not least by AGL as a target price point comparison. Their cap has drifted down since the above was written is now the same as AGL's but hopefully AGL can do better. Vermillion did 2200 odd tests in q3 2016 (100% up on previous year thanks to OVERA replacing OVA1, and are on course to lose $12 million plus this year similar to AGL). Since OVERA is pretty much all they have bar some minor lab work they make AGL look cheap. :) and were once valued at $350 million just on an Ovarian test -now of course their test is on the mkt and FDA approved, but its peformance seems underwhelming. Http://vermillion.com/ Http://www.prnewswire.com/news-releases/vermillion-announces-fda-clearance-of-overa-second-generation-ova1-test-300238668.html Http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=638820
28/11/2016
07:17
gary38: Angle PLC ISSUE OF SHARE OPTIONSSource: UK Regulatory (RNS & others)TIDMAGLRNS Number : 2366QAngle PLC28 November 2016 For immediate release 28 November 2016 ANGLE plc("ANGLE" or the "Company")ISSUE OF SHARE OPTIONSANGLE plc (AIM: AGL; OTCQX: ANPCY), the specialist medtech company, announces that under the shareholder approved Remuneration Policy the Remuneration Committee has approved the issue of 1,500,000 share options to the Company's executive directors. The Remuneration Committee has also approved the issue of 1,805,000 share options to certain staff.Following the issue of these share options, the Company will have outstanding options over a total of 10,365,806 ordinary shares of GBP0.10, representing approximately 11.6% of its issued and to be issued share capital. This leaves approximately 3.9 million options unallocated within the approved limit of up to 16% of the issued and to be issued share capital from time to time.The exercise price for the new share options is 64.50 pence per share, representing the Company's closing mid-market share price on 25 November 2016, being the latest practicable date prior to this announcement. The options are subject to service and/or performance conditions.The new share options granted to the executive directors have a term of ten years and are subject to the performance condition that the share price has risen by at least 100% from the share price when the option is issued.Following the issue of the new share options, the total number of share options held by the executive directors of the Company will be:
04/11/2016
00:42
escapetohome: Perhaps how netsci performs tomorrow on the fda news and the other news CE MARK will give somewhat of a tiny flavour of what agl share price will do on fda news. I know netsci not full fda , thts why i said small flavour !
11/3/2016
11:47
banshee: Indeed, I think AN now expects the AGL Share Price to undergo the financial equivalent of a multiple orgasm in the next few months, if that presentation was anything to go by. He might as well have been holding a sign up saying "This is going to multibag" during his talk.
Angle share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20170428 23:51:42